

GAVRETO Enrollment and Patient Assistance Program Form

Please fax completed form to: 833-397-4435 (833-FXrigel)
For more information, please call RIGEL ONECARE at
833-744-3562 (833-rigelOC)



Monday - Friday, 8am - 8pm EST or visit RigelONECARE.com

PATIENT INFORMATION					
First Name Sex:	Last Name	DOB (mm/dd/yyyy)			
Street Address	City	State Zip			
Home Phone #	Mobile Phone #	Email Address			
PATIENT I	NSURANCE AND PHARMACY PR	EFERENCE			
Please copy both sides of the patient's ins	urance card(s) and include with fax.				
Primary Health Insurance	Prescription Drug Insurance	Secondary Insurance			
Plan Name	Plan Name	Plan Name			
Phone #	Phone #	Phone #			
Policy ID #	Policy ID #	Policy ID #			
Group #	Group #	Group #			
Policy Holder Name (if other than patient)	Rx BIN PCN				
DOB(mm/dd/yyyy)	T CIN				
	/ □ Biologics by McKesson □ Optime Ca Phone #				
	DIAGNOSIS				
Data of Initial Diagnosis(mm/dd/yyyy)				
☐ ICD-10-CM C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung.	ICD-10-CM C73 Malignant neoplasm of thyroid gland.	Other ICD-10			
,					
	CLINICAL INFORMATION				
Has patient been on GAVRETO before? 🗖 Yes	No No				
Line of therapy: \square 1L \square 2L \square Other:					
Smoking history: $\ \square$ Current/former $\ \square$ Ne	ver 🗖 Unknown				
Prior therapy type: 🗖 Platinum-based chemo	therapy $\ \square$ Non-platinum-based chemothe	rapy			
☐ Multikinase inhibitor 〔	PD-L1 inhibitor				

First Name	Last Name			_DOB			
					mm/dd/yyyy)		
PRESCRIBER INFORMATION & PRESCRIPTION							
Prescriber Name		_ Presc	riber Specialty				
Practice Name		_ Practi	ce Contact				
Phone F	ax	_ Stree	t Address				
Email		_ City _		State	Zip		
NPI # DI		_ State	License #				
By signing below, I, as the treating healthcare practitioner, state: (i) This prescription is medically appropriate for this patient and I will be supervising this patient's treatment; (ii) all information supplied to Rigel or its agents ("Rigel") relating to this enrollment form is accurate, and has been obtained pursuant to a separate, valid patient authorization that allows Rigel to contact this patient to provide services relating to (1) treatment and (2) benefit verification and/or pre-authorization. Further, I understand that: (a) any free product provided is for the use of this patient only and shall not be sold or transferred to anyone else, or returned for credit; (b) free product may not be counted toward Medicare Part D out-of-pocket costs, nor claimed for reimbursement from any third-party payer (private or government); (c) I am under no obligation to prescribe any Rigel drug and I have not received and will not receive any benefit from Rigel for prescribing a Rigel drug; and (d) Rigel may revise, change, or terminate programs at any time without notice. I authorize Specialty Pharmacy to initiate any authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited. GAVRETO See full Prescribing Information at GAVRETO.com for detailed product and dosage information.							
Sig: Take 4 (four) capsules (100 mg) k			•				
	,			,			
Prescriber's Signature (no stamp) Dispense as Written (DAW)	/ Date (mm/dd/yyyy)	OR	Prescriber's Signature (no stamp Substitution Allowed	p) Date	(mm/dd/yyyy)		
If this section does not comply with you	ır state's prescription laws, plea:	se provide us	with a compliant prescription.				
Contact RIGEL ONECA	RE for information regard	ing electro	nic prescriptions or other dosi	ng instruct	ions.		
RIGEL'S PR	VACY NOTICE, PATI	ENT AUT	HORIZATION, AND REL	EASE			
program, based on its crite PERSONAL INFORMATION FOR PA pharmacies, my employer, and my he healthcare insurance, benefits, cover. RIGEL ONECARE program ("Persona and vendors (together "Rigel") so tha my treatment with GAVRETO, (ii) coo throughout therapy to discuss my the internal business activities in connect healthcare provider (including my do agree that Personal Information trans Rigel Patient Support Program, I unde eligibility criteria for the program as o USE While Rigel will only use my Pers Information is disclosed it may be re- Personal Information may be used by	eria, you may qualify for IENT SUPPORT I authorize eath insurer(s) to disclose mage limits, appeals, and heal Information") to Rigel Phart training	my healthca y personal i lth records r maceuticals, or coordinate ETO, (iii) pro- poport, (v) co RE program, other third p pone cannot provided und ended purpe will no long prescription	are providers (including my doct information, which may include a elated to my treatment or other lnc., its affiliated companies, but insurance coverage or otherwivide me with information about anduct market research, surveys, and (vi) share such information arties for the purposes describe be secured against unauthorized der this program is contingent understand that I may refuse to the protected by federal privation. I understand that I may refuse the	y, then sign or (s) and the relevant informative obtain p GAVRETO, quality assound above. I undaccess. If I pon my abition of the control of	gn and date. eir staff), my cion related to cormation in the eers, contractors, ayment for civ) contact me urance, and other acies, my insurer(s), nderstand and qualify for the city to meet the ce my Personal derstand my ny authorization		
Personal Information may be used by pharmacies to process my prescription. I understand that I may refuse to provide my authorization or in the future opt out of specific components or services of RIGEL ONECARE, and that my refusal will not affect my ability to receive treatment from my healthcare providers. I understand my pharmacy may receive payment from Rigel for disclosing and using my Persona Information in exchange for providing the services associated with the program or for marketing purposes. TIMEFRAME, COPY, AND REVOCATION I understand that this authorization will expire upon the earlier of (i) five (5) years from this date, (ii) my unenrollment from the Program, or (iii) as required by applicable law. I also understand that the RIGEL ONECARE program may change or end at any time without prior notification. I also understand that I can obtain a copy of my signed authorization upon request and that I can revoke this authorization at any time by calling Rigel at 833-rigelOC (833-744-3562) or 650-449-8646 or by writing to RIGEL ONECARE, 4060 Wedgeway Ct, Earth City, MO 63045. I also understand any revocation will only apply to my healthcare provider(s), pharmacies, and health insurer(s) once they receive notification of my revocation. My signature below certifies that I have received, read, understood, and agree to the Privacy Notice and Patient Authorization to release and use my personal health information. I also attest that I (the patient) am 18 years of age or older.							
Patient Name (print)							
Patient/Representative Signature			Date (mm/	/dd/yyyy)			
			TION DELEACE				

ADDITIONAL COMMUNICATION RELEASE

I understand Rigel may call, email, text message, and mail materials from Rigel at the telephone number(s) and addresses (physical and email) provided on the enrollment form. I understand that my cell phone carrier's standard rates may apply for calls and texts to my cell phone.

First Name	Last Name		DOB		
			(mm/dd/yyyy)		
	PATIENT ASSISTA	ANCE PROGRAM			
Pat	ient to complete this section if a via the Patient Assi	pplying for long-term free drug stance Program (PAP).	ı supply		
Total number of people i	n your home (including yourself): 🏻 1	1 2 1 3 1 4 1 5 1 6+			
U.S. Resident: Tyes	J No				
Total gross monthly hous	ehold income \$				
I hereby certify that I am in product, I must meet the I provided. I understand of an audit. I agree to pro	not insured for (or am rendered uninsur program criteria. I understand that my i that RIGEL ONECARE could ask me for a ovide my financial documentation in a tir etermination of my financial and medica	ncome will be validated through Exper a copy of my IRS 1040 form or other pr mely manner, if so requested. RIGEL OI	rian® based on the information oof of income for the purpose		
provided to me. I represe information provided in t provider's institution, or a federal healthcare progra for any free supply of GA it will cover the product.	es the right at any time, and without noticent and certify that I am a legal resident of this enrollment form is current, complete any other person, must not seek paymer am such as Medicare or Medicaid, or an VRETO capsules supplied under this properties to be responsible for notifying Repolations of the confidence o	of the United States (and U.S. territories e, and accurate. I agree that I, my health at or accept reimbursement from any th y private or other insurance plan, or fro ogram, regardless of whether a payer s IGEL ONECARE if (i) I obtain coverage	s) and verify that the ncare provider, my healthcare hird-party payer, including any om any other person or entity subsequently determines that through another source, state,		
Any changes in insurance coverage and/or financial circumstances while enrolled in the program may affect your ability to continue to receive free product via the PAP. You must reapply for program eligibility at the end of each calendar year. RIGEL ONECARE will reach out to you and your healthcare provider at that time to help with the reenrollment process.					
My signature below cert	ifies that I have received, read, unders	tood, and agree to the Patient Assista	nce Program.		
Patient Name (print)	Repres	entative Name (print)			
Patient/Representative Sign	ature	Date (m	nm/dd/yyyy)		

Page 3 of 3 Please click here or visit GAVRETO.com to see the full Prescribing Information and Patient Information for GAVRETO.